Description of the population
Among the 329 children included in the COBRAPed cohort with available
ISAC data, 6 SRW and 28 SA receiving omalizumab at inclusion were
excluded. Among the 295 remaining children, 47 were classified as (a)
NSRW, 78 as (b) SRW, 108 as (c) NSA, and 62 as (d) SA (Fig 1). Their
main characteristics are presented in Table 1. Children with SRW had
significantly lower birth weight than those with NSRW (3100g [2600,
3430] vs 3380g [3102, 3550], p=0.004) and were more frequently
exposed to second-hand smoke (22.7% vs 2.1%, p=0.004) and visible
mold/dampness (28.2% vs 8.7%, p=0.019). Children with SA had a more
frequent history of FA (26.7% vs 13.2%, p=0.05) and atopic dermatitis
(AD) (46.8% vs 26.9%, p=0.014) than those with NSA. Atopy was found in
61.3% of preschool children and 82.2% of school-age children, without
differences between NSRW and SRW or NSA and SA, respectively.